HPH-15

HPH-15 is an antifibrotic drug with higher AMPK-activation activity than metformin.

The cellular target of this compound is still being investigated, but binding and knockout studies suggest that it is heterogeneous nuclear ribonucleoprotein U. By binding to this nuclear ribonucleoprotein the expression of many proteins can be affected indirectly, by changing mRNA processing.

References

↑ Toma, Tsugumasa; Miyakawa, Nobukazu; Arakaki, Yuiichi; Watanabe, Takuro; Nakahara, Ryosei; Ali, Taha F. S.; Biswas, Tanima; Todaka, Mikio; Kondo, Tatsuya; Fujita, Mikako; Otsuka, Masami; Araki, Eiichi; Tateishi, Hiroshi (2024). "An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models". Diabetologia. 67 (11): 2568–2584. doi:10.1007/s00125-024-06260-y. PMID 39251430.
↑ Toma, Tsugumasa; Nakahara, Ryosei; Otsuka, Masami; Fujita, Mikako; Tateishi, Hiroshi (March 2025). "An anti-cell migration compound that binds to hnRNP U and suppresses nuclear deformation". Bioorganic Chemistry. 156 108215. doi:10.1016/j.bioorg.2025.108215.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by adding missing information.

[1] Toma, Tsugumasa; Miyakawa, Nobukazu; Arakaki, Yuiichi; Watanabe, Takuro; Nakahara, Ryosei; Ali, Taha F. S.; Biswas, Tanima; Todaka, Mikio; Kondo, Tatsuya; Fujita, Mikako; Otsuka, Masami; Araki, Eiichi; Tateishi, Hiroshi (2024). "An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models". Diabetologia. 67 (11): 2568–2584. doi:10.1007/s00125-024-06260-y. PMID 39251430.

[2] Toma, Tsugumasa; Nakahara, Ryosei; Otsuka, Masami; Fujita, Mikako; Tateishi, Hiroshi (March 2025). "An anti-cell migration compound that binds to hnRNP U and suppresses nuclear deformation". Bioorganic Chemistry. 156 108215. doi:10.1016/j.bioorg.2025.108215.